Ashkon Software

   







 

NPSP - NPS Pharmaceuticals, Inc.


NPSP Stock Chart

NPSP Profile

NPS Pharmaceuticals, Inc. logo

NPS Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for patients with rare diseases. The company's lead product, Gattex (teduglutide), is an injectable drug that is used to treat short bowel syndrome (SBS), a rare condition that can cause malnutrition and dehydration due to the inability to absorb nutrients from food. Gattex is the first and only FDA-approved treatment for SBS.

NPS Pharmaceuticals also has other products in development for the treatment of rare diseases, including Natpara (recombinant human parathyroid hormone), which has been approved by the FDA for the treatment of hypoparathyroidism, a rare disorder that can cause low levels of calcium in the blood.

The company was founded in 1986 and is headquartered in Bedminster, New Jersey. In 2015, NPS Pharmaceuticals was acquired by Shire plc, a global biopharmaceutical company, for $5



 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer